In China,lung cancer is a primary cancer type with high incidence and mortality.Risk factors for lung cancer include tobacco use,family history,radiation exposure,and the presence of chronic lung diseases.Most early-stage non-small cell lung cancer(NSCLC)patients miss the optimal timing for ...
文献推荐:大型III期验证性临床研究 | First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial ...
Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC), NADIM now confirms, in its final repo...
2.2013 Updates Non-Small Cell Lung Cancer NCCN Guidelines Index NSCLC Table of Contents Discussion Updates in the 2.2013 version of the Guidelines for Non-Small Cell Lung Cancer from the 1.2013 version include: MS-1 · The discussion section was updated to reflect the changes in the algorithm. ...
In recent years, systemic chemotherapy and molecular targeted therapy have become standard first-line treatments for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). The objective of this survey was to investigate first-line anticancer treatment patterns and gene aberration...
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.What are the subtypes of NSCLC?Squamous cell carcinoma is found in cells that line the airways of the lungs. It is usually found in the middle of the lung. Adenocarcinoma is found in cells that produce mucus. It...
宁波李惠利东部医院,南昌大学第一附属医院的论文被撤稿 2020年2月,宁波市医疗中心李惠利东部医院、南昌大学第一附属医院联合在OncoTargets and Therapy(IF4.0000/4区)期刊上在线发表题为“PVT1 Promo - 金娃学术于20230806发布在抖音,已经收获了77.9万个喜欢,来抖音
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose...
MarcTerronesLung Cancer, 2023 Abstract Non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases which accounts for 80% of newly diagnosed lung cancers. In the previous decade, a new molecular subset ofNSCLCpatients (around 2%) harboring rearrangements of thec-rosoncogene1was define...
Pemetrexed and docetaxel are established therapies in second line non-small cell lung cancer (NSCLC). Comparative data, concerning the two agents in the designated settings, however, are lacking in Chinese patients who account for the largest lung cancer population in the world. We designed and pe...